Prostate Cancer

A test to identify higher risk of developing urinary side effects after radiation in patients with prostate cancer was confirmed by data from a new study.

Use of NeuroSAFE to guide nerve sparing during robot-assisted radical prostatectomy improved patient-reported erectile function.

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal cancers.

As a caregiver, I learned that CyberKnife radiation for metastatic prostate cancer comes with psychological and physical challenges.

FDA expands Pluvicto indication to adults with PSMA+ metastatic castration-resistant prostate cancer previously treated with androgen receptor inhibitors.

SpaceOAR Hydrogel reduced the risk of bowel disorders, the need for colonoscopy and rectal resection following radiation therapy in prostate cancer.

First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone and with other drug combinations.

The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 gozetotide in PSMA-PET scans.

Investigators found that some patients with high-risk nonmetastatic hormone-sensitive prostate cancer were understaged by conventional imaging.

Dr. Chandler Park sat down for an interview with CURE® to discuss the biggest takeaway from the 2025 ASCO GU Symposium in terms of prostate cancer therapy.

The first patient has been enrolled in the phase 3 PROSTATE-IQ trial being conducted in men with prostate cancer recurrence following a prostatectomy.

The FDA has approved Stoboclo and Osenvelt to address skeletal issues faced by patients with cancer.

Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.

The first patient has been dosed in a first-in-human clinical trial evaluating HLD-0915 for metastatic castration-resistant prostate cancer.

Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.

Dr. Chandler Park helps patients with genitourinary cancers, including both prostate and bladder, understand the importance of genetic testing.

After realizing that a stronger support system would have helped me emotionally and spiritually in my cancer journey, I committed myself to being there for my cousin.

Dr. Chandler Park discusses the importance of genetic testing and personalized care in patients with genitourinary cancers.

Patients with intermediate-risk prostate cancer had a 15-year prostate cancer–specific survival rate of 91% with EBRT, with or without short-term ADT.

Among patients with prostate cancer, a high omega-3, low-omega-6 diet with fish oil led to a Ki-67 index decrease.

Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone analogues and ARPIs among patients with metastatic prostate cancer.

Nubeqa plus ADT improved rPFS in mHSPC regardless of disease volume, reducing the risk of radiological progression or death by 46%, per ARANOTE data.

Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to normal after three months.

Among those with intermediate-risk prostate cancer, high PSA levels prior to HIFU led to an increased risk of overall recurrence and treatment failure.

Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower death risk with Talzenna plus Xtandi.